AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00004003
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02460081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02235389
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240838
Drug: acetaminophen extended release caplets
RxNorm normalized name: acetaminophen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00855868
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 MBq (10 mCi), intravenous (IV) injection, single dose
Trial: NCT00855868
Drug: [11C]-PIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB
Trial: NCT03151746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill administered orally 1 hour before planned surgical procedure
Trial: NCT03953729
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start.
Trial: NCT03783676
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive remifentanil bolus and infusion guided by an algorithm.
Trial: NCT03783676
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive normal saline bolus and infusion guided by the remifentanil algorithm.
Trial: NCT00706654
Drug: Placebo depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo depot was supplied in lyophilized vials.
Trial: NCT00706654
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets were identical in appearance to the aripiprazole tablets.
Trial: NCT00356005
Drug: azithromycin plus artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02495766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion
Trial: NCT02978313
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin+LV5FU2
Trial: NCT02978313
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan+LV5FU2
Trial: NCT00895895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
Trial: NCT00895895
Drug: SAM-531 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules SAM-531 1.5 mg, once a day during 52 weeks.
Trial: NCT00895895
Drug: SAM-531 3.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules SAM-531 3.0 mg, once a day during 52 weeks.
Trial: NCT00895895
Drug: SAM-531 5.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
Trial: NCT02931305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
Trial: NCT02956837
Drug: Placebo (Formulation buffer S9b)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Trial: NCT02111863
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
Trial: NCT02637323
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL IA injection
Trial: NCT02637323
Drug: TCA IR 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 mL IA injection
Trial: NCT03332784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-925 Placebo Intravenous Infusion
Trial: NCT00438841
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00040417
Drug: CAMPATH-IH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01744704
Drug: rhNGF 0.5 µg/mL Sentinel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
Trial: NCT01744704
Drug: rhNGF 5 µg/mL Sentinel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 0 represented a sentinel group.
Trial: NCT01744704
Drug: rhNGF 20 µg/mL Sentinel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
Trial: NCT01744704
Drug: rhNGF 20 µg/mL Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
Trial: NCT01744704
Drug: rhNGF 180 µg/mL Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
Trial: NCT01744704
Drug: rhNGF 20 µg/mL Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
Trial: NCT01744704
Drug: rhNGF 60 µg/mL Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
Trial: NCT00991081
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion
Trial: NCT01744704
Drug: rhNGF 180 µg/mL Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
Trial: NCT01744704
Drug: Placebo Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
Trial: NCT01744704
Drug: Placebo Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
Trial: NCT02209181
Drug: JNJ-10450232 / Not yet marketed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
Trial: NCT00000367
Drug: Suicide prevention treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00938405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
Trial: NCT00437021
Drug: Placebo (subcutaneous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
Trial: NCT00437021
Drug: Placebo (scarification)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic normal saline for injection.
Trial: NCT04157933
Drug: 009-A0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
Trial: NCT05846698
Drug: Luo-Bu-Fu-Ke-Bi-RI Pill
RxNorm normalized name: Osteo Bi-Flex Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 pills twice daily
Trial: NCT02132533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
Trial: NCT01026129
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
Trial: NCT01026129
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Trial: NCT02397447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 2000 mg per day for three months
Trial: NCT03568721
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prescription of ibuprofen 400 mg
Trial: NCT03568721
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescription of acetaminophen 500 mg
Trial: NCT00759122
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Trial: NCT00957788
Drug: NST-001
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug.
Trial: NCT00004221
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00269906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01606423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, single dose
Trial: NCT01606423
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, single dose
Trial: NCT04435964
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
Trial: NCT05614440
Drug: Only local anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using articain HCL for inferior alveolar nerve block
Trial: NCT02459080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04511624
Drug: IBI112 dose1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 SC dose1 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 SC dose2 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 SC dose3 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 SC dose4 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 IV dose5 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 SC dose6 Drug:placebo
Trial: NCT04511624
Drug: IBI112 dose7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IBI112 IV dose7 Drug:placebo
Trial: NCT01439867
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
Trial: NCT01065467
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally three times per week.
Trial: NCT01613690
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 is administered via a BREEZHALER device
Trial: NCT04112706
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
Trial: NCT02763215
Drug: Standard of Care Medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
Trial: NCT01780454
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-Cell Depleting Agent
Trial: NCT03121820
Drug: Memantinol tablets, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition
Trial: NCT00672685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMEGA-3 placebo
Trial: NCT04380818
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/24h for 3 days
Trial: NCT04380818
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)
Trial: NCT04380818
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
Trial: NCT01467310
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 to 2.0 mg taken orally every day for seven days.
Trial: NCT02870972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01502046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, One spray per day, up to a maximum of 12 sprays per day.
Trial: NCT02500485
Drug: SHR3824, SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
Trial: NCT01795599
Drug: Gymiso®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02667106
Drug: RX0041-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic study
Trial: NCT03792490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
Trial: NCT00867698
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120
Trial: NCT00203047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for prednisone given daily
Trial: NCT00662597
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00662597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01537692
Drug: BDP HFA Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP HFA Nasal 80mcg
Trial: NCT01537692
Drug: BDP HFA Nasal Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP HFA Nasal 320mcg
Trial: NCT03908892
Drug: zanthoxylum nitidum tincture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
Trial: NCT03908892
Drug: tetracycline ointment
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
Trial: NCT04435392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01333085
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025077
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01249846
Drug: PerioChip ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02506751
Drug: liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
Trial: NCT04389034
Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures
RxNorm normalized name: Brazilian pepper tree pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retrospective analysis of patient records of allergen-specific immunotherapy
Trial: NCT02205775
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 + 40 mg before PCI
Trial: NCT02205775
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg twice before PCI (+ 10 mg ezetimibe)
Trial: NCT02205775
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice before PCI
Trial: NCT02029040
Drug: 0.9 % normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
Trial: NCT01253122
Drug: TRx0037
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02947100
Drug: SCD-Omegatex™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose.
Trial: NCT01442272
Drug: Hidroferol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
Trial: NCT00573547
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine will be dosed at 90 mg once a week
Trial: NCT00664703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Trial: NCT01630590
Drug: Androgen Ablation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
Trial: NCT03080493
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packaged identical to gabapentin dosing